By Author
  By Title
  By Keywords

November 2022, Volume 72, Issue 11

Student's Corner

The tale and trials of Efgartigimod: A newly FDA approved drug for the treatment of Myasthenia gravis

Kashaf Waqar  ( Fifth Year MBBS Student, CMH Multan Institute of Medical Sciences, Multan, Pakistan. )
Anika Zainab  ( Fifth Year MBBS Student, CMH Multan Institute of Medical Sciences, Multan, Pakistan. )

Dear Editor, The significant diminished muscle function is observed in Myasthenia gravis (MG), an autoimmune disease. The muscles of respiration, swallowing, speech, etc., are usually affected.

Journal of the Pakistan Medical Association has agreed to receive and publish manuscripts in accordance with the principles of the following committees: